Evidence for neuroinflammation in Alzheimer's disease

Progress in Neurology and Psychiatry

Volumn 20, Issue 5, 2016, Pages 25-31

  Walters, Anna ^a   Phillips, Emma ^a   Zheng, Rui ^a   Biju, Maya ^b   Kuruvilla, Tarun ^c  

^a Northern Care Alliance NHS Foundation Trust   (United Kingdom)

^b OXFORD HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^c Gloucestershire NHS Foundation Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; DONEPEZIL; ETANERCEPT; FLUORODEOXYGLUCOSE; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; LYMPHOTOXIN; MINOCYCLINE; NAPROXEN; NICERGOLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; TUMOR NECROSIS FACTOR;

ALZHEIMER DISEASE; ASTROCYTE; BLOOD BRAIN BARRIER; CD33 GENE; CENTRAL NERVOUS SYSTEM; CLU GENE; COGNITION; CR1 GENE; CYTOKINE RELEASE; DEGENERATIVE DISEASE; DEMENTIA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GENETICS; HUMAN; IMMUNOPATHOGENESIS; INNATE IMMUNITY; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NEUROIMAGING; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREM2 GENE;

EID: 84992458335     PISSN: 13677543     EISSN: 1931227X     Source Type: Journal    
DOI: 10.1002/pnp.444     Document Type: Review

References (43)

1. Prince M, Guerchet M, McCrone M, et al. Dementia UK: update (second edition). London: Alzheimer’s Society, 2014.
2. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2011; 10(9): 698-712.
3. Hensely K. Neuroinflammation in Alzheimer’s disease: mechanisms, pathologic consequences and potential for therapeutic manipulation. J Alzheimer’s Dis 2010; 21(1): 1-14.
4. Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol 2015; 14: 388-405.
5. Serrano-Pozo A, Mielke ML, Gomez-Isla T, et al. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer’s disease. Am J Pathology 2011; 179(3): 1373-84.
6. Holmes C, Cunningham C, Zotova E, et al. Systemic infection and disease progression Alzheimer disease. Neurology 2009; 73: 768-74.
7. Holmes C, Cunningham C, Zotova E, et al. Proinflammatory cytokines, sickness behaviour and Alzheimer disease. Neurology 2011; 77: 212-18.
8. Syvanen S, Eriksson J. Advances in PET imaging of P-glycoprotein function at the blood-brain barrier. ACS Chemical Neuroscience 2013; 4(2): 225-37.
9. Zhang F, Jiang L. Neuroinflammation in Alzheimer’s disease. Neuropsychiatr Dis Treat 2015; 11: 243-56.
10. Pasqualetti G, Brooks DJ, Edison P. The role of neuroinflammation in dementias. Curr Neurol Neurosci Rep 2015; 15(4): 17.
11. Koenigsknecht-Talboo J, Landreth GE. Microglial phagocytosis induced by fibrillary beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci 2005; 25: 8240-9.
12. Strohmeyer R, Ramirez M, Cole GJ, et al. Association of factor H of the alternative pathway of complement with agrin and complement receptor 3 in Alzheimer’s disease brain. J Neuroimmunol 2002; 131: 135-46.
13. Carrero I, Gonzalo MR, Martin B, et al. Oligomers of beta-amyloid protein (Abeta1-42) induce the activation of cyclooxygenase-2 in astrocytes via an interaction with interleukin-1beta, tumour necrosis factor-alpha, and a nuclear factor kappa-b mechanism in the rat brain. Exp Neurol 2012; 236(2): 215-27.
14. Malik M, Parikh I, Vasquez JB, et al. Genetics ignite focus on microglial inflammation in Alzheimers’ disease. Mol Neurodegener 2015; 10: 52.
15. Jiang T, Yu JT, Zhu XC, et al. Triggering receptor expressed on myeloid cells 2 knockdown exacerbates aging-related neuroinflammation and cognitive deficiency in senescence-accelerated mouse prone 8 mice. Neurobiol Aging 2014; 35(6): 1243-51.
16. Griciuc A, Serrano-Pozzo A, Parrado AR, et al. Alzheimer’s disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 2013; 78: 631-43.
17. Streit WJ, Braak H, Xue QS, et al. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer’s disease. Acta Neuropathol 2009; 118: 475-85.
18. Krabbe G, Halle A, Matyash V, et al. Functional impairment of microglia coincides with beta-amyloid deposition in mice with Alzheimer-like pathology. PLoS One 2013; 8: e60921.
19. Herholz K. Molecular imaging in Alzheimer’s disease. Eur Neurol Rev 2011; 6(1): 16-20.
20. Cagnin A, Brooks DJ, Kennedy AM, et al. In-vivo measurement of activated microglia in dementia. Lancet 2001; 358: 461-7.
21. Edison P, Archer HA, Gerhard A, et al. Microglia, amyloid and cognition in Alzheimer’s disease: an 11CRPk11195-PET and 11CPIB-PET study. Neurobiol Dis 2008; 32: 412-19.
22. Berti V, Pupi A, Mosconi L. PET/CT in diagnosis of dementia. Ann N Y Acad Sci 2011; 1228: 81-92.
23. McGeer PL, McGeer E, Rogers J, et al. Anti-inflammatory drugs and Alzheimer’s disease. Lancet 1990; 335: 1037.
24. McGeer PL, McGeer EG. NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies. Neurobiol Aging 2007; 88: 639-47.
25. Shadfar S, Hwang CJ, Lim MS, et al. Involvement of inflammation in Alzheimers’ disease pathogenesis and therapeutic potential of antiinflammatory agents. Arch Pharm Res 2015; 38: 2106-19.
26. Ferraccioli G, Carbonella A, Gremese E, et al. Rheumatoid arthritis and Alzheimer’s disease: genetic and epigenetic links in inflammatory regulation. Discov Med 2012; 14(79): 379-88.
27. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimers’ disease. Neurology 1993; 43: 1609-11.
28. De Jong D, Jansen R, Hoefnagels W, et al. No effect of one-year treatment with indomethacin on Alzheimer’s disease progression: a randomised controlled trial. PloS One 2008; 3: e147.
29. ADAPT Research Group, Martin BK, Szekely C, et al. Cognitive function over time in the Alzheimer’s disease anti-inflammatory prevention trial (ADAPT): results of a randomised, controlled trial of naproxen and celecoxib. Arch Neurol 2008; 65: 896-905.
30. Breitner JC, Baker LD, Montine TJ, et al. Extended results of the Alzheimer’s disease anti-inflammatory prevention trial. Alzheimer’s Dement 2011; 7: 402-11.
31. Jaturapatpom D, Isaac MG, McCleery J, et al. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer’s disease. Cochrane Database Syst Rev 2012 Feb 15;(2): CD006378.
32. McCaulley ME, Grush KA. Alzheimer’s Disease: Exploring the role of inflammation and implications for treatment. Int J Alzheimers Dis 2015; 2015: 515248.
33. Fillit H, Ding WH, Buee L, et al. Elevated circulating tumour necrosis factor levels in Alzheimer’s disease. Neurosci Lett 1991; 129(2): 318-20.
34. Tobinick E. Perispinal etanercept for treatment of Alzheimers’ disease. Curr Alzheimer Res 2007; 4(5): 550-52.
35. Holmes C, et al. The Safety and Tolerability of Etanercept in Alzheimer’s Disease (STEADI-09): A Phase II double blind randomised placebo controlled trial. Alzheimer’s and Dementia: Journal of the Alzheimer’s Association. Supp. 2014; 10(4): 273
36. Shi JQ, Shen W, Chen J, et al. Anti-TNF-α reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Brain Res 2011; 1368: 239-47.
37. He P, Cheng X, Staufenbiel M, et al Long-term treatment of thalidomide ameliorates amyloid-like pathology through inhibition of β-secretase in a mouse model of Alzheimer’s disease. PLoS One 2013; 8(2): e55091.
38. Combs CK, Johnson DE, Karlo JC, et al. Inflammatory mechanisms in Alzheimer’s disease: Inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARγ agonists. J Neurosci 2000; 20: 558-67.
39. Gold M, Alderton C, Zvartau-Hind M, et al. Rosiglitazone monotherapy in mild to moderate Alzheimer’s disease: Results from a randomised, double blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord 2010; 30: 131-46.
40. Cabral GA, Griffin-Thomas L. Emerging role of the cannabinoid receptor CB2 in immune regulation: Therapeutic prospects for neuroinflammation. Expert Rev Mol Med 2009; 11: e3.
41. Walther S, Schupbach B, Seifritz E, et al. Randomised, controlled crossover trial of dronabinol, 2.5mg, for agitation in 2 patients with dementia. J Clin Psychopharmacol 2011; 31: 256-8.
42. Parachikova A, Vasilevko V, Cribbs DH, et al. Reductions in amyloid-beta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation. J Alzheimers Dis 2010; 21(2): 527-42.
43. Olmos-Alonso A, Schetters ST, Sri S, et al. Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer’s like pathology. Brain 2016; 139(Pt3): 891-907.